Header Logo

Connection

Douglas Corley to Middle Aged

Back to Details
This is a "connection" page, showing publications Douglas Corley has written about Middle Aged.
Douglas Corley
Connection Strength
4.263
Middle Aged
  1. Population-Level Identification of Patients With Lynch Syndrome for Clinical Care, Quality Improvement, and Research. JCO Clin Cancer Inform. 2024 Jun; 8:e2300157.
    View in: PubMed
    Score: 0.102
  2. Colorectal Cancer Screening After Sequential Outreach Components in a Demographically Diverse Cohort. JAMA Netw Open. 2024 Apr 01; 7(4):e245295.
    View in: PubMed
    Score: 0.101
  3. Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer. JAMA. 2022 06 07; 327(21):2114-2122.
    View in: PubMed
    Score: 0.089
  4. Rising Early-onset Colorectal Cancer Incidence Is Not an Artifact of Increased Screening Colonoscopy Use in a Large, Diverse Healthcare System. Gastroenterology. 2022 01; 162(1):325-327.e3.
    View in: PubMed
    Score: 0.085
  5. Validation of Tools for Predicting Incident Adenocarcinoma of the Esophagus or Esophagogastric Junction. Am J Gastroenterol. 2021 05 01; 116(5):949-957.
    View in: PubMed
    Score: 0.083
  6. Influence of Telemedicine-first Intervention on Patient Visit Choice, Postvisit Care, and Patient Satisfaction in Gastroenterology. Gastroenterology. 2021 02; 160(3):929-931.e2.
    View in: PubMed
    Score: 0.080
  7. Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. Gastroenterology. 2020 11; 159(5):1695-1704.e1.
    View in: PubMed
    Score: 0.078
  8. Association of Azithromycin Use With Cardiovascular Mortality. JAMA Netw Open. 2020 06 01; 3(6):e208199.
    View in: PubMed
    Score: 0.078
  9. Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. Clin Gastroenterol Hepatol. 2020 11; 18(12):2734-2741.e6.
    View in: PubMed
    Score: 0.077
  10. Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology. 2020 03; 158(4):884-894.e5.
    View in: PubMed
    Score: 0.074
  11. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology. 2019 01; 156(1):63-74.e6.
    View in: PubMed
    Score: 0.069
  12. When Should Guidelines Change? A Clarion Call for Evidence Regarding the Benefits and Risks of Screening for Colorectal Cancer at Earlier Ages. Gastroenterology. 2018 10; 155(4):947-949.
    View in: PubMed
    Score: 0.069
  13. Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers. Gastrointest Endosc. 2019 01; 89(1):168-176.e3.
    View in: PubMed
    Score: 0.069
  14. Primary care visit use after positive fecal immunochemical test for colorectal cancer screening. Cancer. 2017 Oct 01; 123(19):3744-3753.
    View in: PubMed
    Score: 0.063
  15. Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA. 2017 Apr 25; 317(16):1631-1641.
    View in: PubMed
    Score: 0.063
  16. Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv. 2017 Jun; 11(3):393-400.
    View in: PubMed
    Score: 0.061
  17. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort. Gut. 2018 03; 67(3):418-529.
    View in: PubMed
    Score: 0.061
  18. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology. 2017 03; 152(4):821-829.e1.
    View in: PubMed
    Score: 0.061
  19. Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting. Gastrointest Endosc. 2017 Mar; 85(3):601-610.e2.
    View in: PubMed
    Score: 0.060
  20. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.060
  21. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. Am J Med. 2016 Mar; 129(3):283-91.e5.
    View in: PubMed
    Score: 0.057
  22. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016 Jan; 43(1):73-82.
    View in: PubMed
    Score: 0.056
  23. Ghrelin and Leptin Have a Complex Relationship with Risk of Barrett's Esophagus. Dig Dis Sci. 2016 Jan; 61(1):70-9.
    View in: PubMed
    Score: 0.056
  24. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2360-8.
    View in: PubMed
    Score: 0.055
  25. Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf. 2015 Jul; 24(7):676-83.
    View in: PubMed
    Score: 0.054
  26. Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2256-64.e1-3.
    View in: PubMed
    Score: 0.054
  27. Development and validation of an algorithm for classifying colonoscopy indication. Gastrointest Endosc. 2015 Mar; 81(3):575-582.e4.
    View in: PubMed
    Score: 0.053
  28. Adjusting for patient demographics has minimal effects on rates of adenoma detection in a large, community-based setting. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):739-46.
    View in: PubMed
    Score: 0.053
  29. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. Dig Dis Sci. 2015 Feb; 60(2):436-43.
    View in: PubMed
    Score: 0.052
  30. Dietary guideline adherence for gastroesophageal reflux disease. BMC Gastroenterol. 2014 Aug 14; 14:144.
    View in: PubMed
    Score: 0.052
  31. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014 Oct; 109(10):1586-94.
    View in: PubMed
    Score: 0.052
  32. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 03; 370(14):1298-306.
    View in: PubMed
    Score: 0.051
  33. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013 Dec 11; 310(22):2435-42.
    View in: PubMed
    Score: 0.050
  34. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013 Aug; 145(2):312-9.e1.
    View in: PubMed
    Score: 0.048
  35. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013 Dec; 62(12):1684-91.
    View in: PubMed
    Score: 0.047
  36. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol. 2013 Feb; 11(2):172-80.
    View in: PubMed
    Score: 0.045
  37. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology. 2012 Apr; 142(4):744-53.
    View in: PubMed
    Score: 0.043
  38. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010 Jul; 139(1):93-101.
    View in: PubMed
    Score: 0.038
  39. Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr Cancer. 2009; 61(5):607-16.
    View in: PubMed
    Score: 0.035
  40. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology. 2009 Mar; 136(3):806-15.
    View in: PubMed
    Score: 0.035
  41. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2009 Feb; 58(2):182-8.
    View in: PubMed
    Score: 0.035
  42. Cigarette smoking and the risk of Barrett's esophagus. Cancer Causes Control. 2009 Apr; 20(3):303-11.
    View in: PubMed
    Score: 0.035
  43. Iron intake and body iron stores as risk factors for Barrett's esophagus: a community-based study. Am J Gastroenterol. 2008 Dec; 103(12):2997-3004.
    View in: PubMed
    Score: 0.035
  44. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter. 2008 Oct; 13(5):352-60.
    View in: PubMed
    Score: 0.035
  45. Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus. Am J Gastroenterol. 2008 Jul; 103(7):1614-23; quiz 1624.
    View in: PubMed
    Score: 0.034
  46. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008 Jun; 121(6):525-31.
    View in: PubMed
    Score: 0.034
  47. Hemochromatosis gene status as a risk factor for Barrett's esophagus. Dig Dis Sci. 2008 Dec; 53(12):3095-102.
    View in: PubMed
    Score: 0.034
  48. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):352-8.
    View in: PubMed
    Score: 0.033
  49. Dietary patterns and the risk of Barrett's esophagus. Am J Epidemiol. 2008 Apr 01; 167(7):839-46.
    View in: PubMed
    Score: 0.033
  50. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut. 2008 Jun; 57(6):727-33.
    View in: PubMed
    Score: 0.032
  51. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007 Jul; 133(1):34-41; quiz 311.
    View in: PubMed
    Score: 0.031
  52. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut. 2007 Jun; 56(6):756-62.
    View in: PubMed
    Score: 0.030
  53. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol. 2006 May; 101(5):937-44.
    View in: PubMed
    Score: 0.029
  54. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst. 2004 Sep 15; 96(18):1383-7.
    View in: PubMed
    Score: 0.026
  55. Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death. JAMA Netw Open. 2024 Jul 01; 7(7):e2423671.
    View in: PubMed
    Score: 0.026
  56. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. PLoS One. 2024; 19(6):e0303303.
    View in: PubMed
    Score: 0.026
  57. Population-level impact of the BMJ Rapid Recommendation for colorectal cancer screening: a microsimulation analysis. BMJ Open Gastroenterol. 2024 May 09; 11(1).
    View in: PubMed
    Score: 0.025
  58. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology. 2003 Sep; 125(3):668-76.
    View in: PubMed
    Score: 0.024
  59. Clinical correlates of atypical femoral fracture. Bone. 2012 Jul; 51(1):181-4.
    View in: PubMed
    Score: 0.022
  60. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002 Mar; 122(3):633-40.
    View in: PubMed
    Score: 0.022
  61. Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc. 2011 May; 59(5):916-22.
    View in: PubMed
    Score: 0.021
  62. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2021 04 17; 42(3):369-377.
    View in: PubMed
    Score: 0.021
  63. Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun. 2021 02 12; 12(1):970.
    View in: PubMed
    Score: 0.020
  64. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020 Dec 03; 21(1):801.
    View in: PubMed
    Score: 0.020
  65. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat Commun. 2020 09 04; 11(1):4423.
    View in: PubMed
    Score: 0.020
  66. Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. Am J Hum Genet. 2020 09 03; 107(3):432-444.
    View in: PubMed
    Score: 0.020
  67. Standardized Reporting and Management of Suspicious Findings on Chest CT Imaging Is Associated With Improved Lung Cancer Diagnosis in an Observational Study. Chest. 2020 11; 158(5):2211-2220.
    View in: PubMed
    Score: 0.019
  68. A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors. BMC Cancer. 2020 May 03; 20(1):373.
    View in: PubMed
    Score: 0.019
  69. Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps. Gastroenterology. 2020 08; 159(2):502-511.e2.
    View in: PubMed
    Score: 0.019
  70. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. J Natl Cancer Inst. 2020 03 01; 112(3):238-246.
    View in: PubMed
    Score: 0.019
  71. Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology. 2020 04; 158(5):1274-1286.e12.
    View in: PubMed
    Score: 0.019
  72. Understanding racial disparities in renal cell carcinoma incidence: estimates of population attributable risk in two US populations. Cancer Causes Control. 2020 Jan; 31(1):85-93.
    View in: PubMed
    Score: 0.019
  73. Morbidity and Mortality After Surgery for Nonmalignant Colorectal Polyps: A 10-Year Nationwide Analysis. Am J Gastroenterol. 2019 11; 114(11):1802-1810.
    View in: PubMed
    Score: 0.019
  74. Incidence rates of cardiovascular outcomes in a community-based population of cancer patients. Cancer Med. 2019 12; 8(18):7913-7923.
    View in: PubMed
    Score: 0.019
  75. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019 Oct 02; 367:l5515.
    View in: PubMed
    Score: 0.019
  76. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019 Dec; 30(12):2515-2520.
    View in: PubMed
    Score: 0.018
  77. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. Cancer. 2019 12 01; 125(23):4210-4223.
    View in: PubMed
    Score: 0.018
  78. Colorectal Cancer Screening in People With and Without HIV in an Integrated Health Care Setting. . 2019 07 01; 81(3):284-291.
    View in: PubMed
    Score: 0.018
  79. Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study. Ann Intern Med. 2019 07 02; 171(1):19-26.
    View in: PubMed
    Score: 0.018
  80. Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network. Cancer Causes Control. 2019 Jul; 30(7):747-755.
    View in: PubMed
    Score: 0.018
  81. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018 11; 155(5):1383-1391.e5.
    View in: PubMed
    Score: 0.017
  82. Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey. Support Care Cancer. 2019 Jan; 27(1):147-156.
    View in: PubMed
    Score: 0.017
  83. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology. 2018 04; 154(5):1273-1281.e3.
    View in: PubMed
    Score: 0.016
  84. Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):158-164.
    View in: PubMed
    Score: 0.016
  85. Survival with early diagnosis of invasive gastric mucormycosis in a heart transplant patient. Gastrointest Endosc. 1997 Nov; 46(5):452-4.
    View in: PubMed
    Score: 0.016
  86. Ethnic disparities in renal cell carcinoma: An analysis of Hispanic patients in a single-payer healthcare system. Int J Urol. 2017 10; 24(10):765-770.
    View in: PubMed
    Score: 0.016
  87. Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis. Eur J Epidemiol. 2017 11; 32(11):1007-1017.
    View in: PubMed
    Score: 0.016
  88. Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcare setting. Gastrointest Endosc. 2018 Mar; 87(3):755-765.e1.
    View in: PubMed
    Score: 0.016
  89. Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. Am J Prev Med. 2017 Sep; 53(3):335-344.
    View in: PubMed
    Score: 0.016
  90. Oral bisphosphonates and colorectal cancer. Sci Rep. 2017 03 10; 7:44177.
    View in: PubMed
    Score: 0.016
  91. Racial/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems. Medicine (Baltimore). 2017 Mar; 96(11):e6326.
    View in: PubMed
    Score: 0.015
  92. Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Dig Dis Sci. 2017 03; 62(3):678-688.
    View in: PubMed
    Score: 0.015
  93. Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. J Am Board Fam Med. 2016 11 12; 29(6):672-681.
    View in: PubMed
    Score: 0.015
  94. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018 02; 67(2):291-298.
    View in: PubMed
    Score: 0.015
  95. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2017 10; 66(10):1739-1747.
    View in: PubMed
    Score: 0.015
  96. Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA. Osteoporos Int. 2016 12; 27(12):3477-3484.
    View in: PubMed
    Score: 0.015
  97. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. J Gen Intern Med. 2016 11; 31(11):1323-1330.
    View in: PubMed
    Score: 0.015
  98. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach. J Gen Intern Med. 2016 10; 31(10):1190-7.
    View in: PubMed
    Score: 0.015
  99. Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016 10; 14(10):1412-1419.e3.
    View in: PubMed
    Score: 0.015
  100. Racial disparities in renal cell carcinoma: a single-payer healthcare experience. Cancer Med. 2016 08; 5(8):2101-8.
    View in: PubMed
    Score: 0.015
  101. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol. 2016 10; 14(10):1445-1451.e8.
    View in: PubMed
    Score: 0.015
  102. Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med. 2016 10; 51(4):507-12.
    View in: PubMed
    Score: 0.015
  103. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8.
    View in: PubMed
    Score: 0.015
  104. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med. 2016 Apr; 31(4):372-9.
    View in: PubMed
    Score: 0.015
  105. Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med. 2016 10; 51(4):e107-15.
    View in: PubMed
    Score: 0.015
  106. Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):344-50.
    View in: PubMed
    Score: 0.014
  107. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016 Apr 05; 164(7):456-63.
    View in: PubMed
    Score: 0.014
  108. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016 Apr; 85:142-7.
    View in: PubMed
    Score: 0.014
  109. Oral Bisphosphonate Exposure and the Risk of Upper Gastrointestinal Cancers. PLoS One. 2015; 10(10):e0140180.
    View in: PubMed
    Score: 0.014
  110. Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer. 2016 Mar 01; 138(5):1146-52.
    View in: PubMed
    Score: 0.014
  111. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1692-8.
    View in: PubMed
    Score: 0.014
  112. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. JAMA. 2015 Jun 16; 313(23):2349-58.
    View in: PubMed
    Score: 0.014
  113. MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. PLoS One. 2015; 10(6):e0128617.
    View in: PubMed
    Score: 0.014
  114. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology. 2015 Jun; 148(7):1353-61.e3.
    View in: PubMed
    Score: 0.013
  115. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015 Jan; 11(1):e1004930.
    View in: PubMed
    Score: 0.013
  116. Chronic kidney disease and risk of renal cell carcinoma: differences by race. Epidemiology. 2015 Jan; 26(1):59-67.
    View in: PubMed
    Score: 0.013
  117. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015 Mar; 25(3):208-213.e1.
    View in: PubMed
    Score: 0.013
  118. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis. 2014 Dec; 35(12):2740-7.
    View in: PubMed
    Score: 0.013
  119. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014 Nov; 106(11).
    View in: PubMed
    Score: 0.013
  120. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One. 2014; 9(7):e103508.
    View in: PubMed
    Score: 0.013
  121. Racial/ethnic differences in hip and diaphyseal femur fractures. Osteoporos Int. 2014 Sep; 25(9):2313-8.
    View in: PubMed
    Score: 0.013
  122. Approaches for classifying the indications for colonoscopy using detailed clinical data. BMC Cancer. 2014 Feb 15; 14:95.
    View in: PubMed
    Score: 0.013
  123. Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization. Clin Gastroenterol Hepatol. 2014 Oct; 12(10):1667-76.e1.
    View in: PubMed
    Score: 0.013
  124. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst. 2013 Nov 20; 105(22):1711-8.
    View in: PubMed
    Score: 0.012
  125. Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. J Med Screen. 2013 Dec; 20(4):198-207.
    View in: PubMed
    Score: 0.012
  126. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013 Mar 05; 158(5 Pt 1):312-20.
    View in: PubMed
    Score: 0.012
  127. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012 Dec; 41(6):1706-18.
    View in: PubMed
    Score: 0.011
  128. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet. 2012 Oct; 44(10):1131-6.
    View in: PubMed
    Score: 0.011
  129. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology. 2012 Oct; 143(4):917-26.e1.
    View in: PubMed
    Score: 0.011
  130. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant. 2012 Aug; 12(8):2181-7.
    View in: PubMed
    Score: 0.011
  131. The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol. 2012 Jun; 36(3):306-16.
    View in: PubMed
    Score: 0.011
  132. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 1992 Jan; 79(1):111-6.
    View in: PubMed
    Score: 0.011
  133. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012 Mar; 142(3):442-452.e5; quiz e22-3.
    View in: PubMed
    Score: 0.011
  134. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011 Aug; 60(8):1029-37.
    View in: PubMed
    Score: 0.010
  135. Fracture risk tool validation in an integrated healthcare delivery system. Am J Manag Care. 2011 Mar; 17(3):188-94.
    View in: PubMed
    Score: 0.010
  136. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer. 2010 Jul; 46(11):2067-76.
    View in: PubMed
    Score: 0.010
  137. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis. 2007 Oct; 50(4):552-8.
    View in: PubMed
    Score: 0.008
  138. Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol. 2007 Jun; 102(6):1166-72.
    View in: PubMed
    Score: 0.008
  139. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1366-72; quiz 1301.
    View in: PubMed
    Score: 0.007
  140. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis. 2005 Mar 01; 191(5):761-7.
    View in: PubMed
    Score: 0.007
  141. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004 Jul; 127(1):310-30.
    View in: PubMed
    Score: 0.006
  142. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc. 2002 Feb; 55(2):149-56.
    View in: PubMed
    Score: 0.005

© 2024 Kaiser Permanente